STOCK TITAN
  1. Home
  2. News
  3. BBIO

BridgeBio Pharma Inc - BBIO STOCK NEWS

Welcome to our dedicated news page for BridgeBio Pharma (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on BridgeBio Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BridgeBio Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BridgeBio Pharma's position in the market.

News
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) shared positive results from the Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), conducted by Alexion, AstraZeneca Rare Disease. The results showed consistency with the global BridgeBio ATTRibute-CM Phase III trial, with no mortality reported over the 30-month treatment period. Acoramidis was well-tolerated, with no safety signals of potential clinical concern identified. The findings support local regulatory submission in Japan. The data will be presented at a forthcoming medical meeting and submitted to Japan’s health authority for regulatory review. Acoramidis is an investigational, next-generation, oral, highly potent small molecule stabilizer of transthyretin (TTR), designed to achieve maximal stabilization and preserve native TTR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
clinical trial
-
News
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
Rhea-AI Summary
Invitae (NVTA) announces a partnership with BridgeBio Pharma (BBIO) to advance genetics-based drug discovery for rare diseases. The collaboration aims to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. Invitae's extensive dataset and analytical capabilities will be combined with BridgeBio's expertise in rare disease research and therapeutic development to support the development of transformative medicines for patients with rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
partnership
-
News
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
Rhea-AI Summary
BridgeBio Pharma, Inc. secures strategic financing of up to $1.25 billion from Blue Owl Capital and CPP Investments to support the anticipated launch of acoramidis, a potential therapy for transthyretin amyloid cardiomyopathy (ATTR-CM). The financing includes $500 million in cash from Blue Owl and CPP Investments, a $450 million credit facility from Blue Owl, and the possibility of an additional $300 million credit facility. The royalty agreement with Blue Owl and CPPIB Credit entails a 5% royalty on future global net sales of acoramidis, capped at 1.9 times the invested capital. The refinancing with Blue Owl extends maturity from 2026 to 2029, providing operational flexibility. The financing positions BridgeBio well to launch acoramidis and accelerate its genetic medicine R&D engine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
none
News
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
Rhea-AI Summary
BridgeBio Pharma, Inc. (BBIO) announced positive results from its Phase 3 ATTRibute-CM study of acoramidis for patients with ATTR-CM, demonstrating a significant treatment effect with a 1.8 Win Ratio and 80.7% survival rate. Acoramidis was well-tolerated, with no safety concerns identified. BridgeBio submitted a New Drug Application to the FDA and plans to submit marketing authorization applications to additional regulatory bodies in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
clinical trial
-
News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
BridgeBio Pharma, a commercial-stage biopharmaceutical company (Nasdaq: BBIO), granted 66,963 shares of restricted stock units to twenty-five new employees. Vesting of shares will occur on February 16, 2025, with subsequent vesting on a quarterly basis, subject to continued employment. The awards were made under the Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
-
News
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) to present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
conferences
News
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) has received FDA clearance for the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and highly potent small molecule direct inhibitor of KRASG12C. The drug is expected to significantly improve outcomes for patients with KRASG12C driven malignancies by providing optimal target coverage and addressing mechanisms of adaptive resistance to first generation KRASG12C inhibitors. Enrollment of patients with KRASG12C mutant non-small cell lung cancer into the ONKORAS-101 trial is expected to begin in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
clinical trial
-
News
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) has dosed the first child in PROPEL 3, a Phase 3 clinical trial studying the efficacy and safety of infigratinib in children with achondroplasia. The trial design has received positive feedback from the U.S. FDA and the EU EMA. Data from PROPEL 2's Phase 2 clinical trial showed promising results, supporting infigratinib's potential as an oral, well-tolerated treatment option. BridgeBio expects to begin development of infigratinib in hypochondroplasia by initiating an observational lead-in study in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
clinical trial
-
News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) granted 147,373 shares of restricted stock units to thirty new employees, with vesting schedules and conditions outlined. The awards were made under the Amended and Restated 2019 Inducement Equity Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
none
News
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) has submitted an NDA for acoramidis to the U.S. FDA for the treatment of ATTR-CM. The application was based on positive results from ATTRibute-CM Phase 3 study, demonstrating a highly statistically significant result and rapid clinical benefit on the composite endpoint of ACM and CVH in patients treated with acoramidis. Acoramidis showed an 81% absolute survival rate, improvements on laboratory and functional measures, and was well-tolerated with no safety signals of potential clinical concern.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
Stock BBIO logo
BridgeBio Pharma Inc

Nasdaq:BBIO

BBIO Rankings

#1250 Ranked by Market Cap
#87 Ranked by Stock Gains
N/A Ranked by Dividends

BBIO Stock Data

4.66B
113.02M
5.37%
92.14%
7.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Palo Alto

About BBIO

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.